Corvus Pharmaceuticals, Inc. (CRVS) Tops Q1 EPS by 5c

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q1 EPS of ($0.17), $0.05 better than the analyst estimate of ($0.22).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• nVent to acquire Maverick Power in deal valued up to $2.3B
• PDD Holdings gains on second quarter earnings beat